RSV Challenge Study (CIR320)

The purpose of this study is to test the safety a live recombinant RSV vaccine, administered using a nasal atomizer.

The study is:

• 6 months long
• enrolling healthy adults 18-50 years old
• at least 2 screening visits
• an inpatient challenge phase (about 12 days)
• 2 outpatient follow up visits 
• 1 follow up phone call